|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Debes JD and Tindall DJ: Mechanisms of
androgen-refractory prostate cancer. N Engl J Med. 351:1488–1490.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone
plus prednisone for advanced prostate cancer. N Engl J Med.
351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Petrylak DP1, Tangen CM, Hussain MH, Lara
PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M,
et al: Docetaxel and estramustine compared with mitoxantrone and
prednisone for advanced refractory prostate cancer. N Engl J Med.
351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kelly WK, Curley T, Slovin S, Heller G,
McCaffrey J, Bajorin D, Ciolino A, Regan K, Schwartz M, Kantoff P,
et al: Paclitaxel, estramustine phosphate, and carboplatin in
patients with advanced prostate cancer. J Clin Oncol. 19:44–53.
2001.PubMed/NCBI
|
|
6
|
McGuire WP, Rowinsky EK, Rosenshein NB,
Grumbine FC, Ettinger DS, Armstrong DK and Donehower RC: Taxol: A
unique antineoplastic agent with significant activity in advanced
ovarian epithelial neoplasms. Ann Intern Med. 111:273–279. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rowinsky EK, Burke PJ, Karp JE, Tucker RW,
Ettinger DS and Donehower RC: Phase I and pharmacodynamic study of
taxol in refractory acute leukemias. Cancer Res. 49:4640–4647.
1989.PubMed/NCBI
|
|
8
|
Sunters A, Madureira PA, Pomeranz KM,
Aubert M, Brosens JJ, Cook SJ, Burgering BM, Coombes RC and Lam EW:
Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer
cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res.
66:212–220. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kolomeichuk SN, Terrano DT, Lyle CS,
Sabapathy K and Chambers TC: Distinct signaling pathways of
microtubule inhibitors-vinblastine and Taxol induce JNK-dependent
cell death but through AP-1-dependent and AP-1-independent
mechanisms, respectively. FEBS J. 275:1889–1899. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tudor G, Aguilera A, Halverson DO, Laing
ND and Sausville EA: Susceptibility to drug-induced apoptosis
correlates with differential modulation of Bad, Bcl-2 and Bcl-xL
protein levels. Cell Death Differ. 7:574–586. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lim SJ, Choi MK, Kim MJ and Kim JK:
Alphatocopheryl succinate potentiates the paclitaxel-induced
apoptosis through enforced caspase 8 activation in human H460 lung
cancer cells. Exp Mol Med. 41:737–745. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Saunders DE, Lawrence WD, Christensen C,
Wappler NL, Ruan H and Deppe G: Paclitaxel-induced apoptosis in
MCF-7 breast-cancer cells. Int J Cancer. 70:214–220. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun H and Taneja R: Stra13 expression is
associated with growth arrest and represses transcription through
histone deacetylase (HDAC)-dependent and HDAC-independent
mechanisms. Proc Natl Acad Sci USA. 97:4058–4063. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Honma S, Kawamoto T, Takagi Y, Fujimoto K,
Sato F, Noshiro M, Kato Y and Honma K: Dec1 and Dec2 are regulators
of the mammalian molecular clock. Nature. 419:841–844. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chakrabarti J, Turley H, Campo L, Han C,
Harris AL, Gatter KC and Fox SB: The transcription factor DEC1
(stra13, SHARP2) is associated with the hypoxic response and high
tumour grade in human breast cancers. Br J Cancer. 91:954–958.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Y, Xie M, Yang J, Yang D, Deng R, Wan Y
and Yan B: The expression of antiapoptotic protein survivin is
transcriptionally upregulated by DEC1 primarily through multiple
sp1 binding sites in the proximal promoter. Oncogene. 25:3296–3306.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu Y, Sato F, Bhawal UK, Kawamoto T,
Fujimoto K, Noshiro M, Morohashi S, Kato Y and Kijima H: Basic
helix-loop-helix transcription factors DEC1 and DEC2 regulate the
paclitaxel-induced apoptotic pathway of MCF-7 human breast cancer
cells. Int J Mol Med. 27:491–495. 2011.PubMed/NCBI
|
|
18
|
Liu Y, Sato F, Kawamoto T, Fujimoto K,
Morohashi S, Akasaka H, Kondo J, Wu Y, Noshiro M, Kato Y, et al:
Anti-apoptotic effect of the basic helix-loop-helix (bHLH)
transcription factor DEC2 in human breast cancer cells. Genes
Cells. 15:315–325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu Y, Sato H, Suzuki T, Yoshizawa T,
Morohashi S, Seino H, Kawamoto T, Fujimoto K, Kato Y and Kijima H:
Involvement of c-Myc in the proliferation of MCF-7 human breast
cancer cells induced by bHLH transcription factor DEC2. Int J Mol
Med. 35:815–820. 2015.
|
|
20
|
Lee JT Jr, Steelman LS and McCubrey JA:
Phosphatidylinositol 3′-kinase activation leads to multidrug
resistance protein-1 expression and subsequent chemoresistance in
advanced prostate cancer cells. Cancer Res. 64:8397–8404. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Thin TH, Li L, Chung TK, Sun H and Taneja
R: Stra13 is induced by genotoxic stress and regulates
ionizing-radiation-induced apoptosis. EMBO Rep. 8:401–407. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miyazaki K, Kawamoto T, Tanimoto K,
Nishiyama M, Honda H and Kato Y: Identification of functional
hypoxia response elements in the promoter region of the DEC1 and
DEC2 genes. J Biol Chem. 277:47014–47021. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamada K, Kawata H, Shou Z, Mizutani T,
Noguchi T and Miyamoto K: Insulin induces the expression of the
SHARP-2/Stra13/DEC1 gene via a phosphoinositide 3-kinase pathway. J
Biol Chem. 278:30719–30724. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kon N, Hirota T, Kawamoto T, Kato Y,
Tsubota T and Fukada Y: Activation of TGF-beta/activin signalling
resets the circadian clock through rapid induction of Dec1
transcripts. Nat Cell Biol. 10:1463–1469. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu Y, Sato F, Bhawal UK, Kawamoto T,
Fujimoto K, Noshiro M, Seino H, Morohashi S, Kato Y and Kijima H:
BHLH transcription factor DEC2 regulates pro-apoptotic factor Bim
in human oral cancer HSC-3 cells. Biomed Res. 33:75–82. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu Y, Sato F, Yamada T, Bhawal UK,
Kawamoto T, Fujimoto K, Noshiro M, Seino H, Morohashi S, Hakamada
K, et al: The BHLH transcription factor DEC1 plays an important
role in the epithelial-mesenchymal transition of pancreatic cancer.
Int J Oncol. 41:1337–1346. 2012.PubMed/NCBI
|
